Industry Forecast: Antimicrobial Resistance Diagnostics Market to Generate $5.82 Billion Revenue by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What CAGR Is Anticipated for the Antimicrobial Resistance Diagnostics Market Through 2029?
The market size for diagnostics of antimicrobial resistance has seen significant growth in the past few years, set to expand from $4.10 billion in 2024 to $4.41 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.5%. The surge observed in the historic period can be connected to the rising rates of infections acquired in hospitals, increased misuse of antibiotics in humans and animals, a growing problem with multi-drug resistant organisms, growth in public health surveillance programs, and an increase in diagnostic testing for infectious diseases.
The market size for antimicrobial resistance diagnostics is forecasted to witness significant expansion in the upcoming years, projected to reach $5.82 billion by 2029 with a CAGR of 7.2%. Factors contributing to this growth within the forecast period include the increasing demand for quick diagnostic tools, heightened awareness of antimicrobial stewardship, growing allocation of government funds towards resistance monitoring, widening adoption of point-of-care testing, and a rising necessity for early detection of infections. Some identifiable trends for the forecast period encompass technological progress in diagnostic platforms, new methods for resistance gene detection, an increase in research and development investments, the emergence of portable testing devices, and advancements in multiplex and high-throughput testing.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp
What Market Forces Are Driving The Antimicrobial Resistance Diagnostics Sector In 2025 And Beyond?
The growth of the antimicrobial resistance diagnostics market is expected to be fueled by the increasing incidence of drug-resistant infections. These infections result from the evolution of bacteria, viruses, fungi, or parasites, as they develop mechanisms to withstand exposure to drugs that once effectively treated them, thus rendering traditional treatments useless and infections more difficult to manage. The escalating occurrence of drug-resistant infections is attributed to the excessive use of antibiotics in agriculture, where animals are routinely fed with low-dose antimicrobials, fostering a resistance that can be transferred to humans through the food chain. Instruments like rapid genetic assays and culture-based sensitivity tests, which fall under antimicrobial resistance diagnostics, are pivotal in battling the rising predominance of drug-resistant infections as they allow for the early detection of resistant pathogens, aid in directing targeted therapies, and mitigate the misapplication of wide-ranging antibiotics. An instance that highlights this growing concern is a report released by the UK Health Security Agency, a government body, in November 2023. This report documented a rise in antibiotic-resistant infections in England from 55,792 cases in 2021 to around 58,224 in 2022, indicating a year-on-year increase of 4% in antimicrobial resistance across the nation. As such, the escalating incidence of drug-resistant infections is fueling the expansion of the antimicrobial resistance diagnostics market.
How Is The Global Antimicrobial Resistance Diagnostics Market Categorized By Segments?
The antimicrobial resistance diagnostics market covered in this report is segmented –
1) By Product Type: Kits And Reagents, Instruments And Consumables
2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens
3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies
4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users
Subsegments:
1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media
2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs
What Long-Term Trends Are Likely To Affect The Antimicrobial Resistance Diagnostics Market?
Prominent corporations in the antimicrobial resistance diagnostics market are honing their focus on the creation of novel products like multiplex polymerase chain reaction (PCR) assays, enabling simultaneous detection of numerous pathogens and resistance genes for the enhancement of diagnostic precision and effectiveness. The multiplex PCR aids in identifying different DNA targets in a single reaction, promoting significant time and resource efficiency. For instance, Vela Diagnostics, a molecular diagnostics firm based in Singapore, introduced the PathoKey MP urinary tract infections (UTI) ID and antimicrobial resistance (AMR) PCR test in May 2022. This product facilitates the concurrent detection of 14 UTI pathogens and 14 antimicrobial resistance genes, offering both automated and manual workflows. It also delivers results in as little as four hours, thus bolstering rapid, lab-scale AMR profiling. The PathoKey MP UTI ID & AMR PCR Test aims to equip clinical labs with swifter, high-throughput detection abilities to steer early interventions and effective antibiotic therapy.
Which Firms Are Considered Leaders In The Antimicrobial Resistance Diagnostics Market Space?
Major companies operating in the antimicrobial resistance diagnostics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, bioMérieux S.A., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Seegene Inc., Alifax S.r.l., Accelerate Diagnostics Inc., Lumos Diagnostics Holdings Pty Ltd, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc., OpGen Inc., T2 Biosystems, Jiangsu Medomics Medical Technology Co. Ltd.
Get The Full Report Here:
What Role Do Regional Policies And Investments Play In Antimicrobial Resistance Diagnostics Market Expansion?
North America was the largest region in the antimicrobial resistance diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
